Kura Oncology (NASDAQ:KURA) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $40.00 price objective on the stock.

Other research analysts have also recently issued research reports about the stock. Scotiabank dropped their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. UBS Group dropped their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 8th. BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. Finally, Cantor Fitzgerald raised Kura Oncology to a "strong-buy" rating in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Kura Oncology presently has a consensus rating of "Moderate Buy" and an average price target of $23.89.

Kura Oncology Trading Down 0.3 %

Shares of NASDAQ:KURA traded down $0.02 during mid-day trading on Monday, reaching $6.47. 1,635,415 shares of the company were exchanged, compared to its average volume of 1,157,723. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm's 50-day simple moving average is $6.73 and its 200 day simple moving average is $9.64. The firm has a market cap of $522.63 million, a price-to-earnings ratio of -2.74 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to analyst estimates of $39.08 million. Equities research analysts forecast that Kura Oncology will post -2.44 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KURA. Virtus ETF Advisers LLC boosted its stake in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after acquiring an additional 3,061 shares in the last quarter. Pallas Capital Advisors LLC acquired a new stake in shares of Kura Oncology in the 1st quarter valued at about $66,000. Flower City Capital acquired a new stake in shares of Kura Oncology in the 1st quarter valued at about $79,000. Harbor Advisors LLC purchased a new position in Kura Oncology during the 4th quarter worth approximately $87,000. Finally, E Fund Management Co. Ltd. acquired a new position in Kura Oncology during the fourth quarter worth approximately $90,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.